The Use of Immunoglobulin Therapy for Patients With Primary Immune Deficiency: An Evidence-Based Practice Guideline

Transfusion Medicine Reviews

Volumn 24, Issue SUPPL. 1, 2010, Pages

  Shehata, Nadine ^{a,b,c,d,e,f,g,h,i}   Palda, Valerie ^{a,b,c,d,e,f,g,h,i}   Bowen, Tom ^{a,b,c,d,e,f,g,h,i}   Haddad, Elie ^{a,b,c,d,e,f,g,h,i}   Issekutz, Thomas B ^{a,b,c,d,e,f,g,h,i}   Mazer, Bruce ^{a,b,c,d,e,f,g,h,i}   Schellenberg, Robert ^{a,b,c,d,e,f,g,h,i}   Warrington, Richard ^{a,b,c,d,e,f,g,h,i}   Easton, David ^{a,b,c,d,e,f,g,h,i}   Anderson, David ^{a,b,c,d,e,f,g,h,i}   Hume, Heather ^{a,b,c,d,e,f,g,h,i}  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF MONTREAL   (Canada)

^e DALHOUSIE UNIVERSITY   (Canada)

^f MONTREAL CHILDREN S HOSPITAL   (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h UNIVERSITY OF MANITOBA   (Canada)

ⁱ UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNOGLOBULIN; IGIVNEX; IMMUNOGLOBULIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; UNCLASSIFIED DRUG;

ACUTE SINUSITIS; ANAPHYLAXIS; ARTHRITIS; ARTICLE; ATAXIA TELANGIECTASIA; B CELL LEUKEMIA; CELLULAR IMMUNITY; CHILL; CHRONIC LUNG DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMMON VARIABLE IMMUNODEFICIENCY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE; HEADACHE; HEMOGLOBIN DETERMINATION; HEMOLYSIS; HOME CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNE DEFICIENCY; HYPER IGM SYNDROME; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN A DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; INFECTION; KIDNEY FAILURE; LOW DRUG DOSE; LUNG INFECTION; NAUSEA; NERVE DEGENERATION; NEUROLOGIC DISEASE; NEUTROPHIL COUNT; PNEUMONIA; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; SIDE EFFECT; THROMBOSIS; VIRUS INFECTION; X LINKED AGAMMAGLOBULINEMIA;

CANADA; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGIC FACTORS; PRACTICE GUIDELINES AS TOPIC;

EID: 71249150816     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmrv.2009.09.011     Document Type: Article

References (111)

1. Primary Immune Deficiency Disease in America. The second national survey of patients. Available at. http://www.primaryimmune.org/publications/surveys/second_national_survey_of_patients_(2002).pdf Accessed June 2008
2. Leiva L.E., Zelazco M., Oleastro M., et al. Primary immunodeficiency diseases in Latin America: The second report of the LAGID registry. J Clin Immunol 27 (2007) 101-108
3. Kirkpatrick P., and Riminton S. Primary immunodeficiency diseases in Australia and New Zealand. J Clin Immunol 27 (2007) 517-524
4. Bruton A.C. Agammaglobulinemia. Pediatrics 9 (1952) 722-728
5. Nahirniak S., and Hume H. Guidelines for the use of intravenous immune globulin for primary immune deficiency and solid organ transplantation. Transfus Med Rev 24 Suppl 1 (2010) S1-S6
6. Canadian Task Force on Preventative Health Care. Available at. http://www.ctfphc.org/ Accessed June 2008
7. Ho C., Membe S., Cimon K., et al. Subcutaneous versus intravenous immunoglobulin for primary immunodeficiencies: systematic review and economic evaluation [technology report number 98]. Ottawa: Canadian Agency for Drugs and Technologies in Health. Available at (2008). http://www.cadth.ca/media/pdf/466_Subcutaneous-Versus-Intravenous-Immuno globulin_tr_e.pdf Accessed May 2008
8. Wood P., Stanworth S., Burton J., et al. Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: A systematic review. Clin Exp Immunol 149 (2007) 410-423
9. National Institutes of Health. Intravenous immunoglobulin: prevention and treatment of disease: NIH consensus statement vol. 8 (1990), US Department of Health and Human Services, National Institutes of Health, Washington, DC 1-23
10. Orange J.S., Hossny E.M., Weiler C.R., et al. Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 117 (2006) S525-S553 Review. Erratum in: J Allergy Clin Immunol 2006 Jun; 117(6): 1483. dosage error in text
11. Primary Immunodeficiency Network UK. Administration of intravenous immunoglobulin. PIN Guideline No:2.01. Available at. http://www.ukpin.org.uk/ Accessed February 2008
12. Buckley R.H. Long term use of intravenous immune globulin in patients with primary immunodeficiency diseases: Inadequacy of current dosage practices and approaches to the problem. J Clin Immunol 2 2 Suppl (1982) 15S-21S
13. Oksenhendler E., Gérard L., Fieschi C., et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis 46 (2008) 1547-1554
14. Quinti I., Soresina A., Spadaro G., et al. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol 27 (2007) 308-316
15. Notarangelo L., Casanova J.L., Conley M.E., et al. Primary immunodeficiency diseases: An update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee Meeting in Budapest, 2005. J Allergy Clin Immunol 117 (2006) 883-896
16. Bonilla F.A., Bernstein I.L., Khan D.A., et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 94 Suppl (2005) S1-S63
17. Fleisher T.A., and Oliveira J.B. Functional and molecular evaluation of lymphocytes. J Allergy Clin Immunol 114 (2004) 227-234
18. Conley M.E., Notarangelo L.D., and Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol 93 (1999) 190-197
19. Aghamohammadi A., Pouladi N., Parvaneh N., et al. Mortality and morbidity in common variable immunodeficiency. J Trop Pediatr 53 (2007) 32-38
20. Garbett N.D., Currie D.C., and Cole P.J. Comparison of the clinical efficacy and safety of an intramuscular and an intravenous immunoglobulin preparation for replacement therapy in idiopathic adult onset panhypogammaglobulinaemia. Clin Exp Immunol 76 (1989) 1-7
21. Ammann A.J., Ashman R.F., Buckley R.H., et al. Use of intravenous gamma-globulin in antibody immunodeficiency: Results of a multicenter controlled trial. Clin Immunol Immunopathol 22 (1982) 60-67
22. Nolte M.T., Pirofsky B., Gerritz G.A., et al. Intravenous immunoglobulin therapy for antibody deficiency. Clin Exp Immunol 36 (1979) 237-243
23. Olinder-Nielsen A.M., Granert C., and Forsberg P. Immunoglobulin prophylaxis in 350 adults with IgG subclass deficiency and recurrent respiratory tract infections: A long-term follow-up. Scand J Infect Dis 9 (2007) 44-50
24. Cheng Y.K., Decker P.A., O'Byrne M.M., et al. Clinical and laboratory characteristics of 75 patients with specific polysaccharide antibody deficiency syndrome. Ann Allergy Asthma Immunol 97 (2006) 306-311
25. Pourpak Z., Aghamohammadi A., Sedighipoour L., et al. Effect of regular intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiency. J Microbiol Immunol Infect 39 (2006) 114-120
26. Bayrakci B., Ersoy F., Sarial O., et al. The efficacy of immunoglobulin replacement therapy in the long-term follow-up of the B-cell deficiencies (XLA, HIM, CVID). Turk J Pediatr 47 (2005) 239-246
27. Santaella M.L., Font I., and Disdier O. Common variable immunodeficiency: experience in Puerto Rico. P R Health Sci J 24 (2005) 7-10
28. Aghamohammadi A., Moin M., Farhoudi A., et al. Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia. FEMS Immunol Med Microbiol 40 (2004) 113-118
29. De Garcia J., Vendrell M., Alvarez A., et al. Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. Int Immunopharmacol 4 (2004) 745-753
30. Busse P.J., and Razvi S. Cunningham-Rundles. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 109 (2002) 1001-1004
31. Garcia M.A.M., de Rojas H.F., Manzur N., et al. Respiratory disorders in common variable immunodeficiency. Respir Med 95 (2001) 191-195
32. Quartier P., Debré M., De Blic J., et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: A retrospective survey of 31 patients. J Pediatr 134 (1999) 589-596
33. Ersoy F., and Tezcan I. Sanal O. Effects of intravenous immunoglobulin on clinical and immunological findings of patients with humoral immunodeficiency diseases. Turk J Pediatr 34 (1992) 203-209
34. Liese J.G., Witergerst U., Tympner K.D., et al. High- vs low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia. AJDC 146 (1992) 335-339
35. Williams P., and White A. Wilson JA et al.. Penetration of administered IgG into the maxillary sinus and long-term clinical effects of intravenous immunoglobulin replacement therapy on sinusitis in primary hypogammaglobulinaemia. Acta Otolaryngol 111 (1991) 550-555
36. Galli E., Barbieri C., Cantani A., et al. Treatment with gammaglobulin preparation for intravenous use in children with humoral immunodeficiency: Clinical and immunologic follow-up. Ann Allergy 64 2 Pt. 1 (1990) 147-150
37. Silk H.J., Ambrosino D., and Geha R.S. Effect of intravenous gammaglobulin therapy in IgG2 deficient and IgG2 sufficient children with recurrent infections and poor response to immunization with Hemophilus influenzae type b capsular polysaccharide antigen. Ann Allergy 64 (1990) 21-25
38. Bernatowska E., Madalinski K., Janowicz W., et al. Results of a prospective controlled two-dose crossover study with intravenous immunoglobulin and comparison (retrospective) with plasma treatment. Clin Immunol Immunopathol 43 (1987) 153-162
39. Cunningham-Rundles C., Siegal F.P., et al. Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann Intern Med 101 (1984) 435-439
40. Roifman C.M., Lederman H.M., Lavi S., et al. Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease. Am J Med 79 (1985) 171-174
41. Roifman C.M., Levison H., and Gelfand E.W. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet (1987) 1075-1077
42. Brandt D., and Gershwin M.E. Common variable immune deficiency and autoimmunity. Autoimmun Rev 5 (2006) 465-470
43. Wang J., and Cunningham-Rundles C. Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID). J Autoimmun 25 (2005) 57-62
44. Michel M., Chanet V., Galicier L., et al. Autoimmune thrombocytopenic purpura and common variable immunodeficiency: analysis of 21 cases and review of the literature. Medicine (Baltimore) 83 (2004) 254-263
45. Tcheurekdjian H., Palermo T., and Hostoffer R. Quality of life in common variable immunodeficiency requiring intravenous immunoglobulin therapy. Ann Allergy Asthma Immunol 93 (2004) 160-165
46. Zebracki K., Palermo T.M., Hostoffer R., et al. Health-related quality of life of children with primary immunodeficiency disease: A comparison study. Ann Allergy Asthma Immunol 93 (2004) 557-561
47. Daly P.B., Evans J.H., Kobayashi R.H., et al. Home-based immunoglobulin infusion therapy: Quality of life and patient health perceptions. Ann Allergy 67 (1991) 504-510
48. Sorensen R.U., Kallick M.D., and Berger M. Home treatment of antibody-deficiency syndromes with intravenous immune globulin. J Allergy Clin Immunol 80 (1987) 810-815
49. Kobayashi R.H., Kobayashi A.D., Lee N., et al. Home self-administration of intravenous immunoglobulin therapy in children. Pediatrics 85 (1990) 705-709
50. Ashida E.R., and Saxon A. Home intravenous immunoglobulin therapy by self-administration. J Clin Immunol 6 (1986) 306-309
51. Chapel H., Brennan V., and Delson E. Immunoglobulin replacement therapy by self-infusion at home. Clin Exp Immunol 73 (1988) 160-162
52. Brennan V.M., Cochrane S., Fletcher C., et al. Surveillance of adverse reactions in patients self-infusing intravenous immunoglobulin at home. J Clin Immunol 15 (1995) 116-119
53. Chapel H., and Brennan V. Self-infusion with immunoglobulin at home. J Clin Pathol 44 (1991) 358-359
54. Fasth A., and Nyström J. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. Acta Paediatr 96 (2007) 1474-1478
55. Eijkhout H.W., van Der Meer J.W., Kallenberg C.G., et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med 135 (2001) 165-174
56. Pruzanski W., Sussman G., Dorian W., et al. Relationship of the dose of intravenous gammaglobulin to the prevention of infections in adults with common variable immunodeficiency. Inflammation 20 (1996) 353-359
57. Ochs H.D., Fischer S.H., Wedgewood R.J., et al. Comparison of high-dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases. Am J Med 76 (1984) 78-82
58. Favre O., Leimgruber A., Nicole A., et al. Intravenous immunoglobulin replacement prevents severe and lower respiratory tract infections, but not upper respiratory tract and non-respiratory infections in common variable immune deficiency. Allergy 60 (2005) 385-390
59. Montanaro A., and Pirofsky B. Prolonged interval high-dose intravenous immunoglobulin in patients with primary immunodeficiency states. Am J Med 76 (1984) 67-72
60. Ochs H.D., Davis S.D., and Wedgwood R.J. Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases. J Clin Invest 50 (1971) 2559-2568
61. Avanzini M.A., Björkander J., Söderström R., et al. Qualitative and quantitative analyses of the antibody response elicited by Haemophilus influenzae type b capsular polysaccharide-tetanus toxoid conjugates in adults with IgG subclass deficiencies and frequent infections. Clin Exp Immunol 96 (1994) 54-58
62. Barra A., Bremard-Oury C., Bajart A., et al. Immunogenicity of Haemophilus influenzae type b capsular polysaccharide and its tetanus toxoid conjugate in patients with recurrent infections or humoral immunodeficiency. Int J Clin Lab Res 21 (1992) 231-234
63. Plebani A., Fischer M.B., Meini A., et al. T cell activity and cytokine production in X-linked agammaglobulinemia: implications for vaccination strategies. Int Arch Allergy Immunol 114 (1997) 90-93
64. Webster A.D., Latif A.A., Brenner M.K., et al. Evaluation of test immunisation in the assessment of antibody deficiency syndromes. BMJ 288 (1984) 1864-1866
65. Ko J., Radigan L., and Cunningham-Rundles C. Immune competence and switched memory B cells in common variable immunodeficiency. Clin Immunol 116 (2005) 37-41
66. Goldacker S., Draeger R., Warnatz K., et al. Active vaccination in patients with common variable immunodeficiency (CVID). Clin Immunol 124 (2007) 294-303
67. Rezaei N., Aghamohammadi A., Siadat S.D., et al. Serum bactericidal antibody responses to meningococcal polysaccharide vaccination as a basis for clinical classification of common variable immunodeficiency. Clin Vaccine Immunol 15 (2008) 607-611
68. Piqueras B., Lavenu-Bombled C., Galicier L., et al. Common variable immunodeficiency classification based on impaired B cell memory differentiation correlated with clinical aspects. J Clin Immunol 23 (2003) 385-400
69. Warnatz K., Denz A., Dräger R., et al. Severe deficiency of switched memory B cells (CD27+ IgM-IgD- in subgroups of patients with common variable immunodeficiency: A new approach to classify a heterogeneous disease. Blood 99 (2002) 1544-1551
70. Deeks S.L., Clark M., Scheifele D.W., et al. Serious adverse events associated with bacille Calmette-Guérin vaccine in Canada. Pediatr Infect Dis J 24 (2005) 538-541
71. Casanova J.L., Jouanguy E., Lamhamedi S., et al. Immunological conditions of children with BCG disseminated infection. Lancet 346 (1995) 581 (letter)
72. White W.B., Desbonnet C.R., and Ballow M. Immunoregulatory effects of intravenous immune serum globulin therapy in common variable hypogammaglobulinemia. Am J Med 83 (1987) 431-436
73. Ballow M., White W., and Desbonnet C. Modulation of in vitro synthesis of immunoglobulin and the induction of suppressor activity by therapy with intravenous immune globulin. J Allergy Clin Immunol 84 4 Pt. 2 (1989) 595-601 discussion 601-602
74. Recommendations of the Advisory Committee on Immunization Practices (ACIP): Use of vaccines and immune globulins in persons with altered immunocompetence. MMWR Morb Mortal Wkly Rep 42 (1993) 1-18
75. Kroger A.T., Atkinson W.L., Marcuse E.K., et al. General recommendations on immunization recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 55 (2006) 1-48
76. Canadian Immunization Guide 7th edition. Available at. http://www.phac-aspc.gc.ca/publicat/cig-gci/p03-07-eng.php Accessed May 2008
77. Schiff R.I., Williams L.W., Nelson R.P., et al. Multicenter crossover comparison of the safety and efficacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases. J Clin Immunol 17 (1997) 21-28
78. Matamoros N., De Gracia J., Hernández F., et al. A prospective controlled crossover trial of a new presentation (10% vs. 5%) of a heat-treated intravenous immunoglobulin. Int Immunopharmacol 5 (2005) 619-626 Erratum in: Int Immunopharmacol 513, 2006
79. Lamari F., Karamanos N.K., Papadopoulou-Alataki E., et al. Monitoring of two intravenous immunoglobulin reparations for immunoglobulin G subclasses and specific antibodies to bacterial surface antigens and relation with their levels in treated immunodeficient patients. J Pharm Biomed Anal 22 (2000) 1029-1036
80. Björkander J., Nikoskelainen J., Leibl H., et al. Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia. Vox Sang 90 (2006) 286-293
81. Ebeling F., Baer M., Hormila P., et al. Tolerability and kinetics of a solvent-detergent-treated intravenous immunoglobulin preparation in hypogammaglobulinaemia patients. Vox Sang 69 (1995) 91-94
82. Ballow M., Berger M., Bonilla F.A., et al. Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). Vox Sang 84 (2003) 202-210
83. Roifman C.M., Schroeder H., Berger M., et al. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int Immunopharmacol 3 (2003) 1325-1333
84. Mushiake K., Motoyoshi F., Kondo N., et al. Long-term follow up of patients with common variable immunodeficiency treated with intravenous immunoglobulin: reevaluation of intravenous immunoglobulin replacement therapy. IVIG therapy in CVID. Biotherapy 7 (1993-1994) 101-107
85. Zuhrie S.R., Webster A.D., Davies R., et al. A prospective controlled crossover trial of a new heat-treated intravenous immunoglobulin. Clin Exp Immunol 99 (1995) 10-15
86. Ochs H.D., Pinciaro P.J., and Octagam Study Group. Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases. J Clin Immunol 24 (2004) 309-314
87. Berger M., and Pinciaro P.J. Flebogamma 5% Investigators. Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases. J Clin Immunol 24 (2004) 389-396
88. Wolf H.H., Davies S.V., Borte M., et al. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies. Vox Sang 84 (2003) 45-53
89. Ochs H.D., Buckley R.H., Pirofsky B., et al. Safety and patient acceptability of intravenous immune globulin in 10% maltose. Lancet 2 (1980) 1158-1159
90. Berger M., and Flebogamma 5% DIF Investigators. A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma 5% DIF, the next generation of Flebogamma. J Clin Immunol 27 (2007) 628-633
91. Berger M., Cunningham-Rundles C., Bonilla F.A., et al. Carimune NF Liquid is a safe and effective immunoglobulin replacement therapy in patients with primary immunodeficiency diseases. J Clin Immunol 27 (2007) 503-509
92. Yap P.L., and McClelland D.B. An evaluation of the safety of three intravenous immunoglobulin preparations in patients with primary hypogammaglobulinaemia. J Infect 12 (1986) 5-10
93. Björkander J., Hammarström L., Smith C.I., et al. Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. J Clin Immunol 7 (1987) 8-15
94. Ferreira A., Garcia Rodriguez M.C., Lopez-Trascasa M., et al. Anti-IgA antibodies in selective IgA deficiency and in primary immunodeficient patients treated with gamma-globulin. Clin Immunol Immunopathol 47 (1988) 199-207
95. de Albuquerque Campos R., Sato M.N., and da Silva Duarte A.J. IgG anti-IgA subclasses in common variable immunodeficiency and association with severe adverse reactions to intravenous immunoglobulin therapy. J Clin Immunol 20 (2000) 77-82
96. Eijkhout H.W., van den Broek P.J., and van der Meer J.W. Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy. Neth J Med 61 (2003) 213-217
97. Horn J., Thon V., Bartonkova D., et al. Anti-IgA antibodies in common variable immunodeficiency (CVID): diagnostic workup and therapeutic strategy. Clin Immunol 122 (2007) 156-162
98. Lejtenyi D., and Mazer B. Consistency of protective antibody levels across lots of intravenous immunoglobulin preparations. J Allergy Clin Immunol 121 (2008) 254-255
99. Skull S., and Kemp A. Treatment of hypogammaglobulinaemia with intravenous immunoglobulin, 1973-93. Arch Dis Child 74 (1996) 527-530
100. Siegel J. The product: All intravenous immunoglobulins are not equivalent. Pharmacotherapy 25 11 Pt. 2 (2005) 78S-84S
101. Brennan V.M., Salomé-Bentley N.J., and Chapel H.M. Immunology Nurses Study. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol 133 (2003) 247-251
102. Aghamohammadi A., Farhoudi A., Nikzad M., et al. Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency. Ann Allergy Asthma Immunol 92 (2004) 60-64
103. Struff W.G., Klasser M., Eckert V., et al. Safety monitoring of a polyvalent immunoglobulin preparation: Documentation of 15,548 administrations. Int J Clin Pharmacol Ther 43 (2005) 420-428
104. Debes A., Bauer M., and Kremer S. Tolerability and safety of the intravenous immunoglobulin Octagam: A 10-year prospective observational study. Pharmacoepidemiol Drug Saf 16 (2007) 1038-1047
105. Ballow M. Safety of IGIV therapy and infusion-related adverse events. Immunol Res 38 (2007) 122-132
106. Quinti I., Soresina A., Agostini C., et al. Prospective study on CVID patients with adverse reactions to intravenous or subcutaneous IgG administration. J Clin Immunol 28 (2008) 263-267
107. Ziegner U.H., Kobayashi R.H., Cunningham-Rundles C., et al. Progressive neurodegeneration in patients with primary immunodeficiency disease on IVIG treatment. Clin Immunol 102 (2002) 19-24
108. Scholl P.R. Progressive encephalopathy in primary immunodeficiency disease. Clin Immunol 102 (2002) 1
109. Rudge P., Webster A.D., Revesz T., et al. Encephalomyelitis in primary hypogammaglobulinaemia. Brain 119 (1996) 1-15 (Pt. 1)
110. US. Food and Drug. Letter to manufacturers immune globulin intravenous (Human) (IGIV) required updates to product labeling. Available at. http://www.fda.gov/cber/ltr/igiv101603.htm Accessed June 2008
111. Bresee J.S., Mast E.E., Coleman P.J., et al. Hepatitis C virus infection associated with administration of intravenous immune globulin. A cohort study. JAMA 276 (1996) 1563-1567